奥浦迈(688293) - 投资者关系活动记录表

Financial Performance - In the first three quarters of 2024, the company achieved operating revenue of 216 million CNY, a year-on-year increase of 25.73% [5] - Net profit attributable to shareholders was 27.23 million CNY, a decrease of 36.93% compared to the same period last year [5] - The company's total assets were 2.258 billion CNY, down 1.90% from the end of the previous year [5] - Basic earnings per share were 0.24 CNY, a decline of 36.84% year-on-year [5] Business Segments - Revenue from product sales reached approximately 180 million CNY, an increase of 59.15% year-on-year [5] - Service revenue was 35.51 million CNY, a decrease of 39.05% compared to the previous year [5] - The company’s CDMO (Contract Development and Manufacturing Organization) business showed improvement from the first quarter's low point, indicating a positive trend [5] Market Trends - The biopharmaceutical industry is experiencing fluctuations in market conditions, leading to challenges in fundraising and project execution [5] - Despite these challenges, the sales of cell culture products have significantly increased, reflecting stable demand for high-quality biopharmaceutical raw materials [5] International Growth - The company’s overseas revenue grew by 196.48% compared to the previous year, demonstrating strong global recognition and trust in its products [7] - The number of domestic and international biopharmaceutical companies and research institutions served exceeded 1,600 [7] Operational Efficiency - The net cash flow from operating activities reached 58.78 million CNY, an increase of 72.83% year-on-year, surpassing the growth rate of operating revenue [7] - The company is actively preparing to reapply for high-tech enterprise status after losing its qualification due to tax policy changes [7] Future Outlook - The company remains optimistic about the long-term development of the industry and is committed to enhancing product quality and expanding business boundaries [5] - The completion of the CDMO biopharmaceutical commercialization production platform project is expected to significantly enhance the company's service capabilities [9]